- Home
- CRDO vs LEGN Comparison
CRDO vs LEGN Comparison
Compare CRDO & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDO
- LEGN
- Stock Information
- Founded
- CRDO 2008
- LEGN 2014
- Country
- CRDO Cayman Islands
- LEGN United States
- Employees
- CRDO N/A
- LEGN N/A
- Industry
- CRDO Semiconductors
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- CRDO Technology
- LEGN Health Care
- Exchange
- CRDO Nasdaq
- LEGN Nasdaq
- Market Cap
- CRDO 7.3B
- LEGN 7.0B
- IPO Year
- CRDO 2022
- LEGN 2020
- Fundamental
- Price
- CRDO $61.78
- LEGN $28.91
- Analyst Decision
- CRDO Strong Buy
- LEGN Strong Buy
- Analyst Count
- CRDO 10
- LEGN 13
- Target Price
- CRDO $68.00
- LEGN $75.67
- AVG Volume (30 Days)
- CRDO 3.5M
- LEGN 1.7M
- Earning Date
- CRDO 06-02-2025
- LEGN 05-13-2025
- Dividend Yield
- CRDO N/A
- LEGN N/A
- EPS Growth
- CRDO N/A
- LEGN N/A
- EPS
- CRDO 0.03
- LEGN N/A
- Revenue
- CRDO $327,532,000.00
- LEGN $728,303,000.00
- Revenue This Year
- CRDO $125.51
- LEGN $64.21
- Revenue Next Year
- CRDO $58.82
- LEGN $53.69
- P/E Ratio
- CRDO $2,003.44
- LEGN N/A
- Revenue Growth
- CRDO 99.38
- LEGN 112.46
- 52 Week Low
- CRDO $18.98
- LEGN $27.34
- 52 Week High
- CRDO $86.69
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- CRDO 72.12
- LEGN 39.95
- Support Level
- CRDO $57.21
- LEGN $28.14
- Resistance Level
- CRDO $63.66
- LEGN $31.12
- Average True Range (ATR)
- CRDO 3.00
- LEGN 1.87
- MACD
- CRDO 0.72
- LEGN -0.16
- Stochastic Oscillator
- CRDO 89.56
- LEGN 25.95
About CRDO Credo Technology Group Holding Ltd
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.